(19)
(11)
EP 3 638 225 A1
(12)
(43)
Date of publication:
22.04.2020
Bulletin 2020/17
(21)
Application number:
17734901.6
(22)
Date of filing:
14.06.2017
(51)
International Patent Classification (IPC):
A61K
31/341
(2006.01)
A61K
31/27
(2006.01)
A61K
31/55
(2006.01)
A61K
45/06
(2006.01)
A61K
31/13
(2006.01)
A61K
31/445
(2006.01)
A61P
25/28
(2006.01)
(86)
International application number:
PCT/US2017/037436
(87)
International publication number:
WO 2018/231216
(
20.12.2018
Gazette 2018/51)
(84)
Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD
(71)
Applicant:
Anavex Life Sciences Corp.
New York, NY 10019 (US)
(72)
Inventor:
CECCHI, Marco
Louisville, KY 40204 (US)
(74)
Representative:
Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien
1010 Wien (AT)
(54)
ANAVEX2-73 FOR THE TREATMENT OF ALZHEIMER'S DISEASE